[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"crohns-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:crohns-diseases":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,53,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":4},"100644418","cardiovascular-risk-in-patients-with-ibd-100644418",false,"NCT07663201","Cardiovascular Risk in Patients With IBD","Dissecting the Complexity of Inflammatory Bowel Disease (IBD) A Prospective Study With Focus on Cardiovascular Risk","DICOM-IBD","Inclusion Criteria:\n\nEstablished diagnosis of ulcerative colitis and Crohn's disease\n\nExclusion Criteria:\n\nAge \\> 18 years Not compliant with study protocol",true,"ALL","18 Years",{"count":21,"type":22},300,"ESTIMATED","OBSERVATIONAL","In this study our Research Hospital San Donato Policlinic ask your partipation with the aim to evaluate the risk of cardiovascular complication (i.e. stroke, myocardial infarction) in patients with inflammatory bowel disease. Multiple parameters (therapy, disease activity, life style) and investigations (DNA, stool, lab tests) will be evaluate with the support of artificial intelligence methodologies to better define the cardiovascular risk.",[26,27,28],"Ulcerative Colitis (UC)","Crohn's Diseases","Cardiovascular Risk",[30,31,32,33,34,35,36,37,38,39,40],"Ulcerative colitis","Crohn's disease","Inflammatory bowel disease","Cardiovascular risk","Stroke","Cardiovascular death","Myocardial infarction","Atrial fibrillation","Ischemic heart disease","Major cardiovascular events","Acute Arterial events (i.e. pulmonary embolism)","NOT_YET_RECRUITING","2026-06-17",{"date":44,"type":45},"2026-06-23","ACTUAL",{"date":47,"type":22},"2026-09",{"date":49,"type":22},"2029-12",{"name":51,"class":52},"IRCCS Policlinico S. Donato","OTHER",{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":18,"minAge":60,"maxAge":19,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100625546","the-efficacy-and-safety-of-infliximab-combination-with-azathioprine-in-crohns-disease-in-children-100625546","NCT07424040","The Efficacy and Safety of Infliximab Combination With Azathioprine in Crohn's Disease in Children","Study on the Efficacy and Safety of Infliximab Monotherapy or in Combination With Azathioprine in the Treatment of Crohn's Disease in Children","Inclusion Criteria:\n\n* Diagnose Crohn's disease based on the 2019 Expert Consensus for the Diagnosis and Treatment of Pediatric Inflammatory Bowel Disease.\n* The baseline Pediatric Crohn's Disease Activity Index (PCDAI) value is ≥ 30.\n* None of the patients had received treatment with azathioprine, 6-mercaptopurine, or anti-TNF biological agents before.\n* Patients who received the following adjunctive treatments also meet the participation criteria: acid-suppressing drugs (if the dose was stable for at least 2 weeks before enrollment, it is applicable), enteral nutrition (with a stable plan for 2 weeks). Rectal, intravenous, or oral corticosteroids are not allowed, and they must be discontinued at least 2 weeks before enrollment.\n\nExclusion Criteria:\n\n* Suffering from short bowel syndrome, ostomy surgery, symptomatic stenosis, abscess, or a recent history of abdominal surgery (within 6 months)\n* History of tuberculosis or other granulomatous infections, positive chest imaging or positive tuberculin skin test\n* Recent opportunistic infection history (within 6 months), active hepatitis B or C infection, human immunodeficiency virus infection\n* Multiple sclerosis, cancer\n* Homozygous mutations in NUDT15 or TPMT genes, or heterozygous mutations in at least one of the above genes","6 Years",{"count":62,"type":22},154,"INTERVENTIONAL",[65],"NA","The goal of this clinical trial is to investigate whether there are significant differences in the efficacy of infliximab monotherapy and combined azathioprine therapy in treating pediatric Crohn's disease, as well as whether there are differences in the safety of these two treatment regimens during long-term use. The main questions it aims to answer are:\n\nIs infliximab combined with azathioprine superior to monotherapy in inducing and maintaining remission of Crohn's disease in children? In long-term treatment, can infliximab combined with azathioprine more effectively reduce disease activity and the occurrence of complications, but the incidence of adverse reactions is not higher than that of monotherapy? Researchers will compare the treatment of infliximab combined with azioprine with that of infliximab monotherapy to assess the efficacy and safety of both in inducing and maintaining remission of Crohn's disease in children.\n\nParticipants will:\n\nTake drug ABC or a placebo every day for 4 months Experimental group: Infliximab, administered intravenously at 5mg\u002Fkg every 8 weeks at weeks 0, 2, 6 and thereafter, along with azathioprine, taken orally at 1.5-2.5mg\u002Fkg daily.\n\nControl group: Infliximab (Remicade), administered intravenously at 5mg\u002Fkg every 8 weeks at weeks 0, 2, 6 and thereafter.\n\nA comprehensive disease assessment will be conducted at the hospital in the 14th and 54th weeks.\n\nRecord their symptoms, signs and test results.",[27,68],"Crohn's Disease in Pediatric Patient","2026-02-15",{"date":71,"type":45},"2026-02-20",{"date":73,"type":22},"2026-03-01",{"date":75,"type":22},"2028-11-30",{"name":77,"class":52},"The Children's Hospital of Zhejiang University School of Medicine",4,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":63,"phases":89,"briefSummary":91,"conditions":92,"keywords":93,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":4},"100624887","phase-4-akkermansia-muciniphila-combined-with-infliximab-for-promoting-intestinal-mucosal-healing-in-crohns-disease-100624887","NCT07415473","Akkermansia Muciniphila Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease","A Randomized, Controlled Trial Investigating the Efficacy of Akkermansia Muciniphila Combined With Infliximab in Promoting Intestinal Mucosal Healing in Patients With Crohn's Disease","Inclusion Criteria:\n\n1. Adult patients aged 18 to 75 years.\n2. Documented diagnosis of Crohn's disease established at any time prior to screening by radiological, histological, or endoscopic evidence.\n3. Active Crohn's disease at screening, defined as a Crohn's Disease Activity Index (CDAI) score between 220 and 450 (inclusive).\n4. Adequate cardiac, renal and hepatic function, as assessed by the investigator based on screening laboratory tests, physical examination, and medical history, without findings that would pose an undue risk for study participation.\n5. Willingness and ability to provide written informed consent.\n6. Agreement to undergo all scheduled study procedures, including up to 3 endoscopic evaluations.\n\nExclusion Criteria:\n\n1. Use of any biologic therapy (e.g., infliximab, adalimumab, ustekinumab, vedolizumab) within 8 weeks prior to screening.\n2. Use of systemic antibiotics or any probiotic preparation within 4 weeks prior to screening.\n3. History of any intestinal resection or other Crohn's disease-related surgery.\n4. History of or active chronic or recurrent infectious disease.\n5. History of or current malignancy.\n6. Pregnancy, lactation, or intention to become pregnant during the study period.","75 Years",{"count":88,"type":22},400,[90],"PHASE4","This study aims to evaluate whether the combination of Akkermansia muciniphila with infliximab can improve intestinal mucosal healing in patients with Crohn's disease compared with infliximab alone.",[27],[94,95,96,97,32],"Mucosal healing","Infliximab","Akkermansia muciniphila","Probiotics","2026-02-10",{"date":100,"type":45},"2026-02-17",{"date":102,"type":22},"2026-04-01",{"date":104,"type":22},"2029-03-31",{"name":106,"class":107},"Chinese Medical Association","NETWORK"]